[go: up one dir, main page]

SK3612000A3 - Sustained release tablet formulation to treat parkinson disease - Google Patents

Sustained release tablet formulation to treat parkinson disease Download PDF

Info

Publication number
SK3612000A3
SK3612000A3 SK361-2000A SK3612000A SK3612000A3 SK 3612000 A3 SK3612000 A3 SK 3612000A3 SK 3612000 A SK3612000 A SK 3612000A SK 3612000 A3 SK3612000 A3 SK 3612000A3
Authority
SK
Slovakia
Prior art keywords
hydroxypropylmethylcellulose
pharmaceutical composition
cps
methylamino
composition according
Prior art date
Application number
SK361-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Tzu-Chi Robert Ju
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of SK3612000A3 publication Critical patent/SK3612000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK361-2000A 1997-09-30 1998-09-03 Sustained release tablet formulation to treat parkinson disease SK3612000A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6082797P 1997-09-30 1997-09-30
PCT/US1998/017992 WO1999016442A2 (en) 1997-09-30 1998-09-03 Sustained release tablet formulation to treat parkinson disease

Publications (1)

Publication Number Publication Date
SK3612000A3 true SK3612000A3 (en) 2000-09-12

Family

ID=22031996

Family Applications (1)

Application Number Title Priority Date Filing Date
SK361-2000A SK3612000A3 (en) 1997-09-30 1998-09-03 Sustained release tablet formulation to treat parkinson disease

Country Status (22)

Country Link
US (2) US6197339B1 (fi)
EP (1) EP1017391B1 (fi)
JP (1) JP2001517701A (fi)
KR (1) KR100516095B1 (fi)
CN (1) CN1195518C (fi)
AT (1) ATE297208T1 (fi)
AU (1) AU742941B2 (fi)
BR (1) BR9812687A (fi)
CA (1) CA2301869A1 (fi)
DE (1) DE69830503T2 (fi)
DK (1) DK1017391T3 (fi)
ES (1) ES2242296T3 (fi)
FI (1) FI20000720A7 (fi)
HU (1) HUP0004586A2 (fi)
NO (1) NO320303B1 (fi)
NZ (1) NZ504221A (fi)
PL (1) PL191125B1 (fi)
PT (1) PT1017391E (fi)
RU (1) RU2205007C2 (fi)
SI (1) SI1017391T1 (fi)
SK (1) SK3612000A3 (fi)
WO (1) WO1999016442A2 (fi)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1149100A1 (en) 1999-02-05 2001-10-31 PHARMACIA & UPJOHN COMPANY PROCESS TO PREPARE (5R)-(METHYLAMINO)-5,6-DIHYDRO-4H-IMIDAZO 4,5,1-ij]-QUINOLIN-2(1H)-ONE
BR0009437A (pt) 1999-03-31 2002-01-15 Janssen Pharmaceutica Nv Amido pré-gelatinizado em uma formulação de liberação controlada
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
AU2002360600B2 (en) * 2001-12-11 2007-11-29 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
ES2399880T3 (es) * 2002-03-15 2013-04-04 Cypress Bioscience, Inc. Milnaciprán para el tratamiento del síndrome del intestino irritable
US20050079217A1 (en) * 2002-07-25 2005-04-14 Ganorkar Loksidh D. Sustained-release tablet composition comprising a dopamine receptor agonist
MY136318A (en) * 2002-07-25 2008-09-30 Pharmacia Corp Sustained-release tablet composition
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
PA8578501A1 (es) * 2002-07-25 2005-02-04 Pharmacia Corp Forma de dosificacion una vez al dia de pramipexol
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
JP2006506360A (ja) * 2002-10-04 2006-02-23 ファルマシア・コーポレーション パーキンソン病の治療のための医薬組成物
MXPA05003512A (es) * 2002-10-04 2005-06-03 Pharmacia Corp Composiciones y metodos para el tratamiento de la disfuncion sexual.
JP2006505580A (ja) * 2002-10-25 2006-02-16 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 複素環アミン型化合物の神経保護剤としての使用
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
MXPA05008033A (es) * 2003-01-28 2006-04-28 Collegium Pharmaceutical Inc Composiciones de milnacipran en forma de multiparticulas para administracion oral.
US20050020589A1 (en) * 2003-06-18 2005-01-27 Pfizer Inc. Sustained-release tablet composition comprising a dopamine receptor agonist
ES2355735T5 (es) * 2004-08-13 2014-06-27 Boehringer Ingelheim International Gmbh Formulación en comprimidos de liberación extendida que contiene pramipexol o una de sus sales farmac�uticamente aceptables, método para su fabricación y su uso
EP2431026A1 (en) * 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
CA2619217A1 (en) * 2005-08-15 2007-02-22 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
EP1988875A2 (en) * 2006-02-10 2008-11-12 Boehringer Ingelheim International GmbH Modified release formulation
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ES2379117T3 (es) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP2137171A4 (en) 2007-03-14 2010-05-19 Knopp Neurosciences Inc SYNTHESIS OF BENZOTHIAZOLE DIAMINES SUBSTITUTED AND PURIFIED FROM THE CHIRAL PERSPECTIVE
CA2734491A1 (en) * 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
RU2014114119A (ru) 2011-09-23 2015-10-27 Рош Гликарт Аг Биспецифические анти-egfr/анти igf-1r-антитела
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
SMT202100119T1 (it) 2013-07-12 2021-05-07 Knopp Biosciences Llc Trattamento dei livelli elevati di eosinofili e/o basofili
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
CA3232088A1 (en) * 2021-09-17 2023-03-23 Hinova Pharmaceuticals Inc. Quinoline compound sustained-release tablet and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US5273975A (en) 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
DE69016430T2 (de) * 1989-06-09 1995-06-01 Upjohn Co Heterozyklische amine mit zns-wirksamkeit.
US5000962A (en) 1989-08-25 1991-03-19 Schering Corporation Long acting diltiazem formulation
FR2667864B2 (fr) * 1990-03-07 1994-08-05 Rhone Poulenc Sante Derives de n-phenyl glycinamides, leur preparation et les medicaments les contenant.
GB9605857D0 (en) 1996-03-20 1996-05-22 Tester Richard F Polysaccharides as chemical release systems
CA2173818A1 (fr) 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
DK1017391T3 (da) 2005-08-22
KR100516095B1 (ko) 2005-09-23
CN1195518C (zh) 2005-04-06
HK1030163A1 (en) 2001-04-27
ATE297208T1 (de) 2005-06-15
WO1999016442A2 (en) 1999-04-08
JP2001517701A (ja) 2001-10-09
NO20001624L (no) 2000-03-29
US6197339B1 (en) 2001-03-06
RU2205007C2 (ru) 2003-05-27
NZ504221A (en) 2004-11-26
BR9812687A (pt) 2000-08-22
DE69830503D1 (de) 2005-07-14
EP1017391A2 (en) 2000-07-12
AU742941B2 (en) 2002-01-17
EP1017391B1 (en) 2005-06-08
PL339946A1 (en) 2001-01-15
ES2242296T3 (es) 2005-11-01
FI20000720L (fi) 2000-03-29
US20010053386A1 (en) 2001-12-20
CA2301869A1 (en) 1999-04-08
WO1999016442A3 (en) 1999-06-17
HUP0004586A2 (hu) 2001-06-28
DE69830503T2 (de) 2006-03-16
CN1268890A (zh) 2000-10-04
PL191125B1 (pl) 2006-03-31
AU9296498A (en) 1999-04-23
PT1017391E (pt) 2005-09-30
KR20010030776A (ko) 2001-04-16
FI20000720A7 (fi) 2000-03-29
NO20001624D0 (no) 2000-03-29
SI1017391T1 (sl) 2005-12-31
NO320303B1 (no) 2005-11-21

Similar Documents

Publication Publication Date Title
SK3612000A3 (en) Sustained release tablet formulation to treat parkinson disease
ES2307219T3 (es) Nebivolol y sus sales farmaceuticamente aceptables, procedimiento de preparacion y composiciones farmaceuticas de nebivolol.
SK3898A3 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU616907B2 (en) Melatonin analogues
NZ242191A (en) Crystalline tiagabine hydrochloride monohydrate, preparation and pharmaceutical compositions thereof
JP2025511217A (ja) メセンブリンの塩形態
FR2776291A1 (fr) Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
JPH0253795A (ja) 新規なエステル
NZ541049A (en) Use of 2-amino-2H-quinazoline derivatives for producing therapeutic agents
PL208284B1 (pl) Pochodne benzo[g]chinoliny, kompozycje je zawierające oraz zastosowanie takich pochodnych
PL215012B1 (pl) Nowe pochodne benzo[g]chinoliny, kompozycje farmaceutyczne je zawierajace oraz zastosowania farmaceutyczne tych zwiazków
WO1995004056A1 (en) Heterocyclic amines having central nervous system activity
JPS6230762A (ja) 新規５−オキソ−１−イミダゾリジンアセトアミド誘導体
NL8800412A (nl) Piperazinecarbonzuurderivaat, bereiding ervan en farmaceutische preparaten die het bevatten.
EP1496053A1 (en) Kappa-opioid receptor agonist comprising 2-phenylbenzothiazoline derivative
JPH04178356A (ja) 光学活性なベンジルアルコール誘導体及びその用途
WO2023086432A1 (en) Prodrugs of neurosteroid analogs and uses thereof
CZ20001102A3 (cs) Tabletová formulace pro trvalé uvolňování látky k léčbě Parkinsouovy nemoci
MXPA00002986A (en) Sustained release tablet formulation to treat parkinson disease
US4198414A (en) Compounds and methods for treating diabetic complications
TW202434240A (zh) 苯並氮雜芳環衍生物的藥物組合物及其在醫藥上的應用
PT100133B (pt) Agentes neuroprotectores a base de derivados de iminometano-dibenzo{a,d}ciclo-hepteno, composicoes que os contem, sua utilizacao e processo para a sua preparacao
NO152750B (no) Fremgangsmaate for fremstilling av nitrogen brohode-kondenserte pyrimidinforbindelser
HK1030163B (en) Sustained release tablet formulation to treat parkinson disease
JPS6110558A (ja) 新規なデカハイドロキノリノール誘導体、その製造法及び医薬